002390.KS
HANDOK Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 9,520.00
−1.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 560.9B | 535.1B | 507.4B | 522.7B | 543.8B |
| Cost of Revenue | 402.4B | 390.7B | 349.9B | 371.4B | 370.0B |
| Gross Profit | 158.5B | 144.5B | 157.4B | 151.4B | 173.7B |
| Operating Expenses | |||||
| R&D Expense | 15.8B | 16.7B | 22.6B | 28.7B | 24.0B |
| SG&A Expense | 46.4B | 61.8B | 63.9B | 60.8B | 57.5B |
| General & Admin Expense | 18.6B | 24.7B | 23.6B | 21.9B | 21.2B |
| Selling & Marketing Expense | 27.7B | 37.1B | 40.2B | 38.9B | 36.3B |
| Other Expenses | 88.0B | 62.6B | 70.4B | 64.3B | 63.7B |
| Total Operating Expenses | 150.2B | 141.2B | 156.9B | 153.8B | 145.2B |
| Cost and Expenses | 552.6B | 531.8B | 506.8B | 510.2B | 515.3B |
| Operating Income (EBIT) | 8.3B | 3.3B | 538.5M | 12.6B | 19.5B |
| Non-Operating | |||||
| Interest Income | 1.4B | 1.7B | 924.4M | 1.6B | 470.6M |
| Interest Expense | 19.4B | 19.5B | 17.3B | 13.8B | 8.2B |
| Net Interest Income | (18.0B) | (17.8B) | (16.4B) | (12.2B) | (7.8B) |
| Other Non-Op Income/Expense | (25.6B) | (10.8B) | (62.2B) | (46.1B) | (21.2B) |
| Non-Operating Income (excl Interest) | (12.7B) | — | 44.9B | 32.3B | 13.0B |
| EBT (Pre-Tax Income) | (17.3B) | (7.5B) | (61.7B) | (33.5B) | 7.3B |
| Income Tax Expense | (7.9B) | (5.3B) | (9.0B) | (4.6B) | (3.3B) |
| Bottom Line | |||||
| Net Income | (9.4B) | (2.2B) | (52.6B) | (28.8B) | 10.7B |
| Earnings from Cont. Ops | (9.5B) | (2.2B) | (30.3B) | (28.9B) | 10.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (4.3B) | (2.2B) | (52.6B) | (28.8B) | 10.7B |
| Per Share | |||||
| Basic EPS | (₩358) | (₩163) | (₩3,823) | (₩2,091) | ₩776 |
| Diluted EPS | (₩358) | (₩163) | (₩3,819) | (₩2,091) | ₩776 |
| Revenue Per Share | ₩40,750 | ₩38,880 | ₩36,861 | ₩37,964 | ₩39,490 |
| Shares | |||||
| Basic Shares Outstanding | 13.8M | 13.8M | 13.8M | 13.8M | 13.8M |
| Diluted Shares Outstanding | 13.8M | 13.8M | 13.8M | 13.8M | 13.8M |
| Profitability Metrics | |||||
| EBITDA | 39.9B | 26.8B | (20.8B) | 2.8B | 50.3B |
| D&A | 23.6B | 23.5B | 23.5B | 22.5B | 21.8B |
| EBIT | 16.3B | 3.3B | (44.4B) | (19.7B) | 15.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026